GH Research PLC (NASDAQ:GHRS) Sees Significant Growth in Short Interest

GH Research PLC (NASDAQ:GHRS) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 1,320,000 shares, an increase of 12.8% from the May 31st total of 1,170,000 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average daily volume of 73,500 shares, the days-to-cover ratio is presently 18.0 days.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GHRS. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Tuesday, May 7th. Canaccord Genuity Group raised their target price on GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, May 6th.

GH Research Trading Up 1.2 %

Shares of GH Research stock traded up $0.14 during midday trading on Wednesday, reaching $12.05. The company had a trading volume of 37,794 shares, compared to its average volume of 103,273. The stock has a fifty day simple moving average of $12.32 and a 200 day simple moving average of $9.69. GH Research has a 1-year low of $5.05 and a 1-year high of $14.99. The company has a market capitalization of $626.96 million, a price-to-earnings ratio of -19.44 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last released its earnings results on Friday, May 3rd. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. Sell-side analysts expect that GH Research will post -0.84 earnings per share for the current year.

Institutional Trading of GH Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. AdvisorShares Investments LLC grew its position in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after buying an additional 1,977 shares during the period. PEAK6 Investments LLC increased its stake in shares of GH Research by 72.9% in the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after acquiring an additional 16,991 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of GH Research by 14.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after acquiring an additional 13,579 shares during the period. RTW Investments LP boosted its stake in GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after acquiring an additional 1,158,172 shares during the last quarter. Finally, Lynx1 Capital Management LP grew its holdings in GH Research by 80.1% during the first quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock valued at $35,291,000 after purchasing an additional 1,471,946 shares during the period. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).